EarningsQ2 2026 Earnings Report
DE:2CL Q2 2026 EPS Results
Actual EPS-€0.70
Consensus EPS-€0.51
Beat/MissMissed by -€0.18
One Year Ago EPS-€0.85
DE:2CL Q2 2026 Revenue Results
Actual Revenue€217.41M
Expected Revenue€197.10M
Beat/MissBeat by +€20.31M
YoY Revenue Growth+120.39%
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeAfter Close
Conference CallMonday, August 10, 2026
DE:2CL Upcoming Earnings
BridgeBio Pharma's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2CL Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and meaningful clinical differentiation for Attruby (notably new kidney protection data and multiple supportive RWE analyses), substantial pipeline progress with three NDAs under review and clear commercial readiness, and a fortified balance sheet following a $1.0B preferred equity raise. Offsetting these positives were the disappointing CARDIO-TTRansform result (undermining combination therapy), higher operating expenses to fund multiple launches, and some revenue mix/one-time revenue headwinds. On balance, the company portrayed momentum across commercial, clinical, and financial fronts with manageable near-term risks tied to execution, upcoming regulatory decisions, and competitive/payer dynamics.Company Guidance
Strong Revenue Growth Driven by Attruby
Net product revenue for Attruby was $222.4M in Q2 2026 vs $71.5M in Q2 2025, an increase of $150.9M; total company revenues were $243.7M vs $110.6M a year ago (+$133.1M). Attruby delivered another quarter with >$35M sequential U.S. revenue growth and was described as the fastest-growing brand in the space at ~23%.
Compelling Real-World Evidence and Renal Protection for Attruby
Published data showed direct kidney-protective effects (improved chronic eGFR slope and reduced urinary albumin-to-creatinine ratio). Subgroup analysis: patients with acute eGFR dips ≥4.89 mL/min/1.73 m² favored acoramidis with HR 0.42 for all-cause mortality or CV hospitalization (p=0.006) and HR 0.34 for CV hospitalization alone (p=0.002). Independent RWE cited a 37% reduction in composite CV events and 34% reduction in hospitalizations at 6 months versus tafamidis; company preprint showed a 34% reduction in diuretic intensification, HF hospitalization, and mortality.
Three Late-Stage Programs Transitioned to Regulatory Review
NDAs submitted for BBP-418 (LGMD2I/R9), encaleret (ADH1), and infigratinib (achondroplasia). BBP-418 NDA accepted with Priority Review (PDUFA Nov 27, 2026, no advisory committee). Encaleret NDA accepted with Priority Review (PDUFA May 8, 2027) and MAA submitted to EMA. Infigratinib NDA submitted (aiming for MAA in Q4 and potential approval mid-2027).
Commercial and Launch Readiness Built Out
Field sales, medical affairs, and commercial teams have been hired and trained for upcoming launches (BBP-418, encaleret, infigratinib); patient-identification engines and payer preapproval engagement are underway. BBP-418: >500 genetically confirmed patients identified in the U.S.; company cites concentrated prescriber base (~150 MDA centers).
Significant Capital Raise Strengthens Balance Sheet
Cash, cash equivalents, and marketable securities were $720.2M as of June 30, 2026; subsequent $1.0B preferred equity investment closed July 1, 2026 (led by Sixth Street), bringing pro forma cash to ~ $1.7B to fund launches and operations.
Improved Operating Loss and Growing Royalty Stream
Loss from operations improved to $107.1M in Q2 2026 vs $134.3M in Q2 2025 — an improvement of $27.2M (~20% year-over-year). Royalty revenue increased to $15.4M in Q2 2026 vs $1.6M prior-year, driven by BEYONTTRA sales in EU and Japan.
Positive Phase 3 / Clinical Readouts and Publications
Infigratinib PROPEL 3 Phase 3 results published in NEJM showing a 0.37 SD improvement in arm span (p<0.0001) and other meaningful efficacy measures. BBP-418 data described as profound biochemical and functional improvements; GondolaBio program reported positive Phase 2a EPP data and regulatory guidance allowing a Phase 2b/3 that could support registration.
Growing Patient Identification for Encaleret and Broader Opportunities
More than 2,200 patients identified in ICD-10 claims for ADH1 (up ~300 since Q1); ~70 new patients/month being coded; company also pursuing RECLAIM-HP Phase 3 for chronic hypoparathyroidism (readout expected in ~18 months), with a broader chronic hypoparathyroidism population estimated at ~200,000 in US+EU.
DE:2CL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed